Haleon plc (HLN)vsLifecore Biomedical Inc. (LFCR)
HLN
Haleon plc
$9.19
-0.33%
HEALTHCARE · Cap: $44.28B
LFCR
Lifecore Biomedical Inc.
$4.12
+0.73%
HEALTHCARE · Cap: $164.66M
Smart Verdict
WallStSmart Research — data-driven comparison
Haleon plc generates 8514% more annual revenue ($11.15B vs $129.47M). HLN leads profitability with a 14.5% profit margin vs -23.8%. HLN appears more attractively valued with a PEG of 2.48. HLN earns a higher WallStSmart Score of 51/100 (C-).
HLN
Buy51
out of 100
Grade: C-
LFCR
Avoid30
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Strong operational efficiency at 23.9%
No standout strengths identified
Areas to Watch
Expensive relative to growth rate
2.2% revenue growth
Grey zone — moderate risk
Earnings declined 4.5%
0.0% earnings growth
Smaller company, higher risk/reward
Expensive relative to growth rate
ROE of -76.4% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : HLN
The strongest argument for HLN centers on Price/Book, Operating Margin.
Bull Case : LFCR
LFCR has a balanced fundamental profile.
Bear Case : HLN
The primary concerns for HLN are PEG Ratio, Revenue Growth, Altman Z-Score.
Bear Case : LFCR
The primary concerns for LFCR are EPS Growth, Market Cap, PEG Ratio. Debt-to-equity of 9.64 is elevated, increasing financial risk.
Key Dynamics to Monitor
HLN profiles as a value stock while LFCR is a turnaround play — different risk/reward profiles.
LFCR carries more volatility with a beta of 1.09 — expect wider price swings.
HLN is growing revenue faster at 2.2% — sustainability is the question.
HLN generates stronger free cash flow (792M), providing more financial flexibility.
Bottom Line
HLN scores higher overall (51/100 vs 30/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Haleon plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Haleon plc (HLN) is a leading global consumer health company, emerging as a spin-off from GlaxoSmithKline, dedicated to providing innovative health solutions through a robust portfolio of trusted brands, including Sensodyne, Panadol, and Voltaren. Focused on key segments such as oral care, pain relief, and dietary supplements, Haleon addresses evolving consumer needs while leveraging strong brand equity for sustained market presence. The company's commitment to sustainability and ongoing innovation, alongside strategic investments in product development, positions Haleon favorably for long-term growth and enhanced health outcomes, ultimately maximizing value for shareholders.
Visit Website →Lifecore Biomedical Inc.
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Lifecore Biomedical, Inc., is an integrated contract development and manufacturing organization in the United States and internationally. The company is headquartered in Santa Maria, California.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?